Timothy Seijung Oh
5 Papers
6 Citations
Timothy Seijung Oh is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies
Anand Patel,James J. Yoon,Hannah Johnston,Evan C. Chen,Madelyn E. Burkart,Timothy Seijung Oh,Sunil Iyer,Ellen Madarang,Iyana Gross,Terrence Bradley,Yasmin Abaza,Jacqueline S. Garcia,Rory M. Shallis,Guru Subramanian Guru Murthy,Vikas Gupta,Kristen Pettit,John F. Cursio,Olatoyosi Odenike +17 more
TL;DR: In this article , a multi-center retrospective analysis was performed to characterize outcomes of patients with MPN-AP/BP in the current era of myeloid therapies via a multiscale retrospective analysis.
5
Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
Narendranath Epperla,Rui Li,Pallawi Torka,Lauren Shea,Reem Karmali,Andrea Anampa-Guzmán,Timothy Seijung Oh,Kathryn G. Lindsey,I. Brian Greenwell,Sayan Mullick Chowdhury,Kaitlin Annunzio,Beth Christian,Geoffrey Shouse,Alex F. Herrera,Nancy L. Bartlett,Natalie S Grover,Adam J. Olszewski +16 more
TL;DR: In this paper , the prognostic relevance of early relapse (POD24) defined as relapse/progression within 24 months from systemic therapy initiation in a large US cohort was evaluated.
2
Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study
Narendranath Epperla,Qiuhong Zhao,Lauren Shea,Reem Karmali,Pallawi Torka,Timothy Seijung Oh,Andrea Anampa-Guzmán,Ximena Jordan Bruno,Elvira Umyarova,Kathryn G. Lindsey,I. Brian Greenwell,Sayan Mullick Chowdhury,Yazeed Sawalha,Beth Christian,Natalie S Grover,Nancy L. Bartlett,Adam J. Olszewski +16 more
TL;DR: In this article , the authors evaluated the impact of monoclonal protein (M-protein) at diagnosis on outcomes in patients with marginal zone lymphoma (MZL) in 8 US medical centers.
2
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers
Adam Zayac,Daniel J. Landsburg,Mitchell E Hughes,Emily C. Ayers,M. Girton,Marie Hu,Amy Beckman,Shaoying Li,L. J. Medeiros,Habibe Kurt,Jose Sandoval-Sus,M. A. Ansari-Lari,Shalin Kothari,A. Kress,Mina L Xu,Pallawi Torka,Suchitra Sundaram,Stephen D Smith,Kikkeri N. Naresh,Yasmin H Karimi,Narendranath Epperla,David A. Bond,Andrew M Evens,Karan Pandya,Seema G Naik,Manali Kamdar,Bradley M. Haverkos,Reem Karmali,Timothy Seijung Oh,Julie M. Vose,Heather Nutsch,Paul Rubinstein,Amina Chaudhry,Adam J. Olszewski +33 more
TL;DR: The characteristics and outcomes of patients with HGBL, NOS diagnosed in 17 academic centers across the United States were examined, with rates of complete response (CR), progression-free (PFS) and overall survival (OS) estimated with 95% confidence intervals (CI).
1
Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
Eric P. Winer,Yael Flamand,Rory M. Shallis,Jessica M. Stempel,Aaron D Goldberg,Maximilian F. Stahl,Anand Patel,Adam S. DuVall,Yasmin Abaza,Timothy Seijung Oh,Karen Ma,Talha Badar,Mark R. Litzow,Vamsi Kota,Danielle Bradshaw,Hari S. Raman,Marlise R. Luskin,Richard Stone,Daniel J. DeAngelo +18 more
TL;DR: In this paper , the impact of FLT3 mutational status in pts with NPM1+ AML and the role of SCT in patients >60 years with ITD negative (ITDneg).